A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Hozzl · 2022-12-29T16:33:52Z

Explore the details of Senate Bill 4152 A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships. currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 4:33 PM

Congressional Summary of S 4152

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 4152

Bill S 4152 is currently in the status of Bill Introduced since May 5, 2022. Bill S 4152 was introduced during Congress 117 and was introduced to the Senate on May 5, 2022. Bill S 4152's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of May 5, 2022

Bipartisan Support of Bill S 4152

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4152

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4152

A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Start holding our government accountable!